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Abstract
Background:  The development of effective chemopreventive agents against cigarette smoke-induced lung
cancer could be greatly facilitated by suitable laboratory animal models, such as animals treated with the tobacco-
specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In the current study, we
established a novel lung cancer model in Wistar rats treated with NNK. Using this model, we assessed the effects
of two chemopreventive agents, aspirin and phenethyl isothiocyanate (PEITC), on tumor progression.
Methods: First, rats were treated with a single-dose of NNK by intratracheal instillation; control rats received
iodized oil. The animals were then sacrificed on the indicated day after drug administration and examined for
tumors in the target organs. PCNA, p63 and COX-2 expression were analyzed in the preneoplastic lung lesions.
Second, rats were treated with a single-dose of NNK (25 mg/kg body weight) in the absence or presence of aspirin
and/or PEITC in the daily diet. The control group received only the vehicle in the regular diet. The animals were
sacrificed on day 91 after bronchial instillation of NNK. Lungs were collected and processed for histopathological
and immunohistochemical assays.
Results: NNK induced preneoplastic lesions in lungs, including 33.3% alveolar hyperplasia and 55.6% alveolar
atypical dysplasia. COX-2 expression increased similarly in alveolar hyperplasia and alveolar atypical dysplasia,
while PCNA expression increased more significantly in the latter than the former. No p63 expression was
detected in the preneoplastic lesions. In the second study, the incidences of alveolar atypical dysplasia were
reduced to 10%, 10% and 0%, respectively, in the aspirin, PEITC and aspirin and PEITC groups, compared with
62.5% in the carcinogen-treated control group. COX-2 expression decreased after dietary aspirin or aspirin and
PEITC treatment. PCNA expression was significantly reduced in the aspirin and PEITC group.
Conclusion: (1) A single dose of 25 mg/kg body weight NNK by intratracheal instillation is sufficient to induce
preneoplastic lesions in Wistar rat lungs. (2) COX-2 takes part in NNK-induced tumorigenesis but is not involved
in proliferation. (3) Aspirin and PEITC have protective effects in the early stages of tumor progression initiated
by NNK.
Published: 29 May 2007
BMC Cancer 2007, 7:90 doi:10.1186/1471-2407-7-90
Received: 16 August 2006
Accepted: 29 May 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/90
© 2007 Ye et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
Page 2 of 10
(page number not for citation purposes)
Background
Lung cancer is strongly associated with cigarette smoking
[1]. It is the single best-documented risk factor for all lung
cancer types [2]. Each cigarette contains a mixture of car-
cinogens, including the tobacco-specific nitrosamine
NNK and a small dose of polycyclic aromatic hydrocar-
bons (PAHs) among others, along with tumor promoters
and co-carcinogens [3,4]. The complex of PAHs and the
tobacco-specific nitrosamine NNK in cigarette smoke is
the mixture that is most likely to be involved in the induc-
tion of human lung cancer.
It is suggested that NNK is strongly related to human pul-
monary adenocarcinoma [2,5,6]. An etiological role of
NNK in the induction of human lung cancer is supported
by evidence showing that NNK is activated to form a
DNA-damaging agent in human lung tissue [7], and that
the lung is an important target organ for NNK-induced
carcinogenesis in rodents. NNK induces lung adenocarci-
noma in mice, rats and Syrian golden hamsters, inde-
pendently of administration route [8-11]. Although these
models are widely used to explore the genetic mecha-
nism(s) of pulmonary neoplasia and its chemopreven-
tion, some weaknesses cannot be ignored. First, the
animals are usually given carcinogens by intraperitoneal
(i.p.) or subcutaneous injection (s.c.) or oral administra-
tion, and administration takes a long time. Second, neo-
plasia can be found in other organs besides lung, e.g. nasal
cavity, liver, esophagus and pancreas. Third, a high inci-
dence of spontaneous tumors including pulmonary neo-
plasia has been observed in some special strains used in
this model, e.g. A/J mouse.
In the present work, we show that a single dose of NNK by
intratracheal instillation induces preneoplastic lesions in
Wistar rat lungs. This is the first time, to our knowledge,
that early preneoplastic lesions have been reported in
NNK-treated Wistar rats. The advantages and limitations
of the model in chemoprevention studies are discussed
and we also suggest that two chemopreventive agents,
PEITC and aspirin, protect the rats against NNK-induced
tumorigenesis during the early stages of tumor develop-
ment. Understanding the different early steps of lung tum-
origenesis caused by NNK might facilitate the
development of more effective strategies for the preven-
tion, early diagnosis and treatment of lung cancer.
Methods
Animals
Female Wister rats, 6–7 weeks, 200 ± 10 g, were purchased
from the animal center of Hubei College of Traditional
Chinese Medicine. The animals were housed in plastic
cages under standard laboratory condition (25°C; 40%
relative humidity; 12 h dark/light cycle) with food and
water. We received approval for the production and use of
laboratory animals (rodent, rabbit, dog and monkey)
from Hubei Province Department of Science and Technol-
ogy, license No. SYXK ( ) – 2003 – 0013.
Chemicals
NNK was purchased from Chemsyn Science Laboratories.
PEITC and aspirin were from Sigma-Aldrich.
Tumor induction
NNK was dissolved in iodized oil at a stock concentration
of 50 mg/ml. The animals were randomly assigned to 2
groups. Group 1, comprising 18 animals, were instilled
with NNK into the left lobe using the method previously
established [12]. In brief: after the animal was anesthe-
tized, it was hung on a slanted surgical board and its vocal
cord was exposed. Using a blunt ZY-type 12-gauge needle,
NNK was instilled into the left lower lobe at a dose of 25
mg/kg body weight. Group 2, comprising 10 animals,
were instilled with 0.1 ml iodized oil into the left lung as
control. After instillation, the rats were given streptomycin
(250 mg/kg body weight) and penicillin (100000 U/kg
body weight) by muscle injection for 7 days to preclude
infections.
DSA of X-ray photography
Every animal was X-rayed immediately after instillation to
identify the location of the iodized oil, and again after 92
days to observe changes in the left lobe.
Histopathology
All animals that died during the study or were sacrificed
under ether anesthesia received a complete necropsy and
histopathological examination. Lungs were perfused
intratracheally with 10% neutral buffered formalin (NBF)
and immersed in 10% NFB for fixation. Major tissues were
fixed and preserved in 10% NFB, processed and trimmed,
embedded in paraffin, sectioned at a thickness of 3–4 µm,
and stained with hematoxylin and eosin for microscopic
examination. The following tissues were examined micro-
scopically for gross lesions and tissue masses: bone and
marrow, heart, large intestine, small intestine, kidney,
liver, lung and associated lymph nodes, spleen, stomach,
nasal cavity. Three transverse step sections were prepared
to observe tumor development in the left lung of each rat.
The sections from group 1, which received NNK, were
divided into alveolar hyperplasia, alveolar atypical dyspla-
sia, adenoma and adenocarcinoma. The following criteria
for diagnostic evaluation were used: alveolar hyperplasia
– alveolar structure of lung is present, proliferation of cells
obliterates normal alveolar space, and the proliferated
cells are homogeneous and slightly enlarged without cyto-
logical atypia. Alveolar atypical dysplasia – alveolar struc-
ture of lung is largely present, and the proliferated cells are
larger and show enlarged nuclei, hyperchromasia and
nuclear-cytoplasmic reversal. Adenoma – alveolar struc-BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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ture is largely absent and replaced by proliferated cells
with or without cytological atypia. Adenocarcinoma –
tumor composed of glandular, papillary, or solid masses
with cytological atypia. Preneoplastic lesions include alve-
olar hyperplasia and atypical dysplasia.
Transmission electron microscopy
To identify the origin of the proliferated cells in the group
treated with NNK (group 1), small pieces of specimens
from the left lung were fixed in 5% phosphate buffered
glutaraldehyde for 2 hours, then postfixed in 1% osmium
tetroxide, dehydrated in a graded series of ethanol and
acetone and embedded in epoxy resin 618. Ultrathin sec-
tions were stained with uranyl acetate and lead citrate and
examined with a Hitachi H-600 electron microscope.
Immunohistochemistry
Antibodies against CK (AE1/AE3), PCNA, p63, COX-2
(rabbit polyclonal) were purchased from NeoMarkers
(Lab Vision, Fremont, CA). IHC staining was performed
using a modified avidin-biotin complex method
described by Kobayashi [13]. Sections of formalin-fixed
and paraffin-embedded tissue samples from gross lesions
of the lung were deparaffinized in xylene and hydrated
through a graded alcohol series before being microwaved
in citrate buffer (pH 6) for 10 minutes, and the slides were
then allowed to cool at room temperature for 30 minutes.
Endogenous peroxidase was blocked with 3% hydrogen
peroxide for 15 minutes, and the tissues were incubated
with normal blocking goat serum. Subsequently, the
slides were incubated with primary antibody (dilution,
1:200) overnight at 4°C, washed, stained with bioti-
nylated second antibody for 30 minutes, incubated with
strepavidin horseradish peroxidase enzyme at room tem-
perature for 20 minutes, then treated with 3', 3-diami-
nobenzidine chromogen (DAB) for 3 minutes at room
temperature and counterstained with hematoxylin.
PCNA immunostaining [14] was scored by counting at
least 500 cells in representative high power fields. Every
stained nucleus was considered positive, irrespective of
intensity. In cases where staining was heterogeneous in
the section, the fields examined included those with the
highest and those with the lowest percentages of stained
cells. The percentage of positive stained cells was recorded
as the PCNA labeling index (LI). In preneoplastic lesions,
p63 was scored on the following basis: 0 for no staining;
1 for basal layer staining; 2 for basal and parabasal layer
staining; and 3 for full thickness staining. In the speci-
mens immunostained for COX-2, the distribution (the
percentage of positive cells) and the intensity of staining
were assessed semiquantitatively. The scoring criteria were
similar to those used for human specimens [15]. Both the
number of positive cells and the intensity of staining were
evaluated as follows. Number of positive cells: none, 0;
focal (one third of cells stained), 1; multifocal (two third
of cells stained), 2; and diffuse (most cells stained), 3.
Intensity of staining: none, 0; mild (between 0 and 2), 1;
and strong (clearly identified by × 40 magnification), 2.
The scores for distribution and intensity were added. The
score for each specimen was then recorded as the mean
overall score of five × 40 objective fields. All samples were
independently scored by two blinded investigators.
Chemopreventive agents
Wistar rats (6–7 weeks of age, 200 ± 10 g body weight)
were purchased from the animal center of Hubei Chinese
Medical College. The animals were housed in plastic cages
under standard laboratory condition (25°C; 40% relative
humidity; 12 h dark/light cycle) with food and water ad
libitum for 1 week. After the acclimation period, they were
randomly allocated to 5 groups: (A) aspirin, 0.5 g/kg diet,
10 rats; (B) PEITC, 0.5 g/kg diet, 10 rats; (C) aspirin, 0.5
g/kg and PEITC, 0.5 g/kg diet, 10 rats; (D) positive con-
trol, 8 rats; (E) negative control, 9 rats. Each rat in groups
A-D was given a single dose of NNK (25 mg/kg body
weight, intratracheal instillation). Rats in group E were
instilled with 0.1 ml iodized oil without NNK. Six hours
later, the rats in groups A, B and C were fed their special
diets, while groups D and E were maintained on the nor-
mal diet as before. The normal diet was produced by the
Laboratory of Wuhan University on the basis of rat for-
mula feeds, which are regulated by standard GB 14924-
2001 published by the People's Republic of China. The
dietary treatments were continued until the end of the
experimental period. The rats were weighed weekly and
food consumption was measured every other day. At 3
months (91 days) after NNK administration, the rats were
killed and the lungs were processed for histopathological
and immunohistochemical examination.
Statistics
Analyses were done using SPSS software version 13.0.
One-way ANOVA followed by Dunnett's T3 test was used
to evaluate the changes of PCNA protein expression
among the groups. One-way ANOVA followed by Tukey's
test was used to evaluate changes in COX-2 protein
expression, food consumption and body weight among
the groups. The incidences of alveolar hyperplasia and
dysplasia were compared among the chemopreventive
experiment groups using the χ2 test.
Results
Instillation region
All animal pulmograms showed that the iodized oil was
located in the left inferior lobe (Fig. 1), and the image was
gradually attenuated with time. Three months (92 days)
after instillation, the image had almost disappeared.BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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Morphological changes
Group 1 was killed on day 92. In this group, 10 rats
(55.56%) were seen by the naked eye to have firm gray
nodules in the left inferior lobe, ranging in size from
about 2 to 5 mm; 2 rats had pulmonary emphysema; the
others had no obvious changes. Microscopy revealed that
6 rats (33.33%) had alveolar hyperplasia: the alveolar
structure of lung was present; the proliferated cells oblit-
erated the normal alveolar space but had no obvious cyto-
logical atypia. Ten rats (55.56%) showed alveolar atypical
dysplasia: the alveolar structure of lung was largely
present; the proliferated cells were larger and showed
enlarged nuclei, hyperchromasia and nuclear-cytoplasmic
reversal (Fig. 2). Only 2 out of 18 rats had squamous
metaplasia of the bronchial epithelium, and none had
dysplasia or CIS. No pathological changes appeared in
any of the control groups.
Origin of proliferated cells in the NNK-treated group
In order to determine the origin of the proliferated cells,
we studied CK and S-100 expression in lung specimens.
CK was positive in some proliferated cells, but S-100 was
negative. In the thickened alveolar septa, some cells
expressed both CK and PCNA (Fig. 3A, B). By transmis-
sion electron microscopy, the proliferated cells had lamel-
lar body-like structures; the mitochondria in these cells
were swollen (Fig. 4).
COX-2, p63 and PCNA expression in preneoplastic lesions 
in the NNK-treated rats
In normal rat lung tissue, bronchial mucosa epithelial
cells and smooth muscle cells stained positively for COX-
2. Some basal cells in normal bronchial epithelium
expressed p63 and PCNA. In the control group only 2
specimens showed no reaction for p63, the mean (SD)
scores for COX-2 and PCNA are 0.68 (0.33) and 1.16
(0.53), respectively. In preneoplastic lesions in the NNK-
treated group, the mean (SD) scores for COX-2 were 2.93
(0.24) and 3.34 (0.43) in alveolar hyperplasia and alveo-
lar atypical dysplasia, respectively. p63 protein was not
expressed anywhere in these specimens except in the
bronchial mucosa. The mean (SD) PCNA indices were
18.57 (2.60) and 24.25 (3.34) in alveolar hyperplasia and
alveolar atypical dysplasia, respectively. Compared with
normal tissues, COX-2 expression also clearly increased in
alveolar hyperplasia, but there was no difference between
CK and PCNA expression in alveolar septa of Wistar rats  exposed to NNK Figure 3
CK and PCNA expression in alveolar septa of Wistar 
rats exposed to NNK. Parallel sections of thickened alveo-
lar septa were stained with CK antibody (A) and PCNA-spe-
cific antibody (B). Arrows indicate cells that expressed both 
CK and PCNA. Magnification × 400.
X-ray photographs of NNK-treated rats Figure 1
X-ray photographs of NNK-treated rats. X-ray photo-
graphs showed the carcinogenic iodized oil located in the left 
lobe after instillation.
Photomicrographs of typical lung lesions in NNK-treated  Wistar rats Figure 2
Photomicrographs of typical lung lesions in NNK-
treated Wistar rats. (A) Alveolar epithelial hyperplasia in a 
Wistar rat (magnification × 200). (B) Dysplasia occurred in 
the alveolar region. Some of the alveolar structure was 
absent and replaced by proliferated cells (magnification × 
200). (C) Proliferated cells with increased cellular atypia 
(magnification × 400).BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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alveolar hyperplasia and alveolar atypical dysplasia. The
PCNA labeling index increased in cases of alveolar hyper-
plasia, and a significant difference was detected between
alveolar hyperplasia and alveolar atypical dysplasia (Fig.
5).
Chemoprevention
In the second part of our study, we explored the ability of
PEITC and aspirin to inhibit the effect of NNK in the Wis-
tar rat model of preneoplastic lesions. Figure 6 presents
the food consumption and body weight throughout the
experiment. Food consumption was lower in groups B
(PEITC) and C (aspirin and PEITC) than in the other
groups during week 1 (P < 0.01), especially on the second
day, and lower than in group E (negative control) during
week 9 (P < 0.05). There were no effects on body weight.
In the carcinogen-treated control group (group D), the
incidences of alveolar hyperplasia and alveolar atypical
dysplasia were 25.00% and 62.50% respectively. Progres-
sion to adenocarcinoma was inhibited in groups A, B and
C. Treatment with aspirin and/or PEITC reduced the alve-
olar dysplasia and improved the lung structure (Fig. 7).
The results are summarized in Table 1. The incidence of
atypical dysplasia was significantly lower in groups A
(aspirin), B (PEITC) and C (aspirin and PEITC) than in
the carcinogen controls (group D). In group A, aspirin sig-
nificantly (P < 0.01) decreased atypical dysplasia by
84.00%. In group B, PEITC also significantly (P < 0.01)
decreased atypical dysplasia by 84.00%. In group C, atyp-
ical dysplasia was reduced by 100.00%. Alveolar hyper-
plasia was also reduced in group C but the reduction was
not statistically significant. No alveolar hyperplasia or
atypical alveolar dysplasia appeared in any of the negative
controls, which were not treated with NNK (group E).
The specimens were further analyzed for proliferation and
expression of COX-2 to elucidate the mechanism by
which aspirin or/and PEITC reduced alveolar atypical dys-
plasia. The data presented in Table 2 summarize the
PCNA labeling indices and COX-2 scores for each group.
The percentage of PCNA positive cells was significantly
reduced by aspirin and PEITC in group C, and also
reduced in groups A and B by aspirin or PEITC. However,
the reduction was not statistically significant. COX-2
Expression of COX-2 and PCNA in preneoplastic lung  lesions of Wistar rats exposed to NNK Figure 5
Expression of COX-2 and PCNA in preneoplastic 
lung lesions of Wistar rats exposed to NNK. A and B 
show immunohistochemical staining for COX-2 and PCNA 
in normal lung tissues of rats. A, COX-2; B, PCNA. C and D 
show immunohistochemical staining for COX-2 and PCNA 
in alveolar hyperplasia of NNK-treated Wistar rats. C, COX-
2; D, PCNA. E and F show immunohistochemical staining for 
COX-2 and PCNA in alveolar dysplasia of NNK-treated 
Wistar rats. E, COX-2; F, PCNA. Magnification × 200.
Transmission electron microscopy of proliferated cells in  Wistar rats exposed to NNK Figure 4
Transmission electron microscopy of proliferated 
cells in Wistar rats exposed to NNK. The proliferated 
cells had lamellar body-like structures (arrows). Magnification 
× 4000.BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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expression was not changed by PEITC treatment; in con-
trast, it was clearly reduced by aspirin or by aspirin and
PEITC.
Discussion
The Wistar rat has been used widely in experimental
research. Unlike the A/J mouse, it is not susceptible to the
development of adenomas that progress with time to car-
cinomas. In 1984, we successfully established a protocol
for inducing squamous cell carcinoma in Wistar rat lungs
by MCA [12]. In this model, we could obtain different
morphological stages in the mutistep process of lung tum-
origenesis by controlling the survival time: hyperplasia,
squamous metaplasia, atypical dysplasia, CIS, invasive
carcinoma and metastatic carcinoma. Using this model,
we explored many aspects of the molecular mechanism of
formation of pulmonary squamous cell carcinoma. This
study demonstrated for the first time that a single-dose
intratracheal instillation of NNK could produce preneo-
plastic lesions in Wistar rat lungs. Three months after
instillation, the rats treated with NNK had no obviously
pathological lesions in any of the main organs except the
lung. First, this protocol has the advantage of being safe,
since the carcinogens are handled only once. To our
knowledge, only one other single dose protocol has been
reported to induce adenomas in A/J mice by the i.p. route:
Hecht developed a rapid single-dose protocol for induc-
ing lung tumors in A/J mice by NNK in 1989. A single
intraperitoneal injection of NNK at a dose of 2 mg per
mouse was sufficient to induce an average of 10–12 lung
adenomas in each animal [16]. Various investigators have
used this model to demonstrate the efficacies of chemo-
preventive agents. Second, our model is suitable for inves-
tigating somatic changes during lung tumorigenesis,
including changes in the blood. Although the organospe-
cificity of NNK for the lung is remarkable, most studies
have involved systemic administration of the compound,
e.g. orally or by i.p. or s.c. injection, so tumors were also
found in other organs [17-20]. This may make it difficult
for researchers to distinguish specific changes in lung tum-
origenesis-related serum proteins. In our study, NNK was
administered locally into the respiratory tract. Lesions
were found only locally in the lung. The model could be
used to identify prognostic and monitoring factors from
blood samples for early detection. Third, intratracheal
instillation is more relevant to inhalation of tobacco
smoke by people. The results show that alveolar hyperpla-
sia and atypical dysplasia can be observed in this model.
Some proliferated cells in these lesions had abundant
cytoplasm and usually expressed CK abundantly; electron
Table 1: The effects of aspirin or/and PEITC on lung tumorigenesis in Wistar rats treated with NNK
Group Number of rat Alveolar hyperplasia Alveolar atypical dysplasia
n Incidence (%) n Incidence (%) 
[Decreasea]
A. Aspirin 10 6 60.00 1 10.00 [84.00%]
B. PEITC 10 4 40.00 1 10.00 [84.00%]
C. Aspirin + PEITC 10 1 10.00 0 0.00 [100.00%]
D. Positive control 8 2 25.00* 5 62.50**
E .  N e g a t i v e  c o n t r o l 90000
a Compared with the incidence of alveolar atypical dysplasia in group D
*p < 0.05 when compared with negative control group by Fisher's exact probability test.
**p < 0.01 when compared with negative control group by Fisher's exact probability test.
p < 0.05 when compared with positive control group by Fisher's exact probability test.
p < 0.01 when compared with positive control group by Fisher's exact probability test.
Food consumption and body weight in groups A-E Figure 6
Food consumption and body weight in groups A-E. A, 
food consumption was measured every other day and aver-
aged for all rats in the group; B, body weights were measured 
weekly and averaged for all rats in the group. Values shown 
are means.
Aspirin and/or PEITC inhibit lung tumorigenesis in Wistar  rats after NNK instillation Figure 7
Aspirin and/or PEITC inhibit lung tumorigenesis in 
Wistar rats after NNK instillation. Treatment with aspi-
rin and/or PEITC reduced alveolar dysplasia and improved 
lung structure after 91 days. A, NNK-treated group; B, aspi-
rin group; C, aspirin and PEITC group. Magnification × 100.BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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microscopy showed that most of these cells had lamellar
body-like structures. This suggests that the proliferated
cells may derive from type 2 pneumocytes. According to
the dosage reported by Schuller [21], we tested the carci-
nogenic potency of NNK in preliminary studies on Wistar
rats in doses ranging from 25–50 mg/kg body weight over
3 to 6 months, but no dose or time response was
observed. Long-term studies will be carried out to test our
expectation that the preneoplastic lesions described here
will in fact progress to adenocarcinomas. With further
development, this should furnish an excellent model for
preneoplastic lesions, carcinomas and metastatic carcino-
mas.
Comparing these two models morphologically, the MCA-
induced lung preneoplastic lesions were squamous meta-
plasia, squamous atypical dysplasia and CIS. The NNK-
induced preneoplastic lung lesions were alveolar hyper-
plasia and atypical dysplasia. This indicates that MCA and
NNK have different target locations in lung tumorigene-
sis.
Carcinogens such as NNK require metabolic activation to
exert their carcinogenic effects; there are competing
detoxification pathways, and the balance between meta-
bolic activation and detoxification differs among individ-
uals and will affect cancer risk. Prostaglandin (PG)-
endoperoxide synthase (cyclooxygenase) enzymes (COX)
may play important roles in the oxidation of NNK in lung,
and they also catalyze the conversion of certain polynu-
clear aromatic hydrocarbons and/or metabolites to the
ultimately carcinogenic diol epoxides [22,23]. Two iso-
forms of COX, COX-1 and COX-2, have been identified as
the enzymes responsible for the production of prostaglan-
dins. COX-2 increases in many neoplastic tissues and is
inducible by cytokines, growth factors and chemical car-
cinogens. Multiple lines of evidence suggest that COX-2 is
also important in carcinogenesis. El-Bayoumy et al. [24]
observed that increased COX-2 expression correlated with
the development of lung tumors induced by NNK. In
humans, overexpression of COX-2 has also been associ-
ated with lung cancer, specifically with adenocarcinomas
[25,26]. Hida et al. [25] reported that COX-2 was overex-
pressed in 16 of 23 adenocarcinomas (70%) and one of
three AAH. Increased COX-2 expression in precursor
lesions of human lung adenocarcinoma was also observed
by Yukio et al. [27]. This supports a role for COX-2 in the
earliest stages of lung adenocarcinoma progression. Our
data provide further confirmation of this role. COX-2 pro-
tein levels clearly increased in alveolar hyperplasia and
alveolar atypical dysplasia, and the COX-2 score corre-
lated with the PCNA labeling index. COX-2 expression in
squamous cell carcinoma is very different from that in
lung adenocarcinoma, studies have demonstrated that
COX-2 protein and mRNA expression was significantly
lower in squamous cell carcinoma than in adenocarci-
noma [26,28-30].
The recently discovered factor p63 is the most ancient
member of the p53 family [31]. p63 amplification or
overexpression is often found in NSCLC, specifically in
squamous cell carcinomas [32-34]. To study the role of
p63 in tumorigenesis, we analyzed the frequency and tim-
ing of p63 protein expression by IHC on NNK-induced
lesions. We found that p63 was not overexpressed in any
lesion induced by NNK. Conflicting data have been pub-
lished regarding the immunoreactivity of p63 in AAH
[35], indicating a need for further investigation.
Aspirin is a traditional non-steroidal anti-inflammatory
drug (NSAID). There is some evidence that regular and
prolonged aspirin use is associated with a reduced risk of
lung cancer [36-41]. One proposed mechanism for the
chemopreventive properties of aspirin and other NSAIDs
entails the inhibition of COX-2 [42], the enzyme that reg-
ulates prostaglandin production. Prostaglandin E2 plays a
key role in the accelerated proliferation of lung cancer cell
lines [43]. The results from the first part of our study sug-
gested that COX-2 is important in NNK-induced tumori-
genesis. So, in the second part of the study, we used the
NNK model to observe the chemopreventive efficacy of
aspirin via COX-2 suppression. Our results confirmed that
Table 2: The effects of aspirin or/and PEITC on the expressions of PCNA and COX-2
Group Number of rat % Cells Positive for PCNA
Mean (SD)
Scores for COX-2 
Mean (SD)
A.aspirin 10 12.05(8.81) 2.08(0.72)
B.PEITC 10 10.92(11.55) 2.34(0.95)
C.asprin + PEITC 10 4.25(5.27) 1.60(0.73)
D.Positive control 8 24.48(9.14) ** 3.13(0.88) **
E.Negative control 9 1.17(0.56) 0.67(0.35)
*p < 0.05 when compared with negative control group.
**p < 0.01 when compared with negative control group.
 p < 0.05 when compared with positive control group.
p < 0.01 when compared with positive control group.BMC Cancer 2007, 7:90 http://www.biomedcentral.com/1471-2407/7/90
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25 mg/kg body weight aspirin per day significantly
reduced COX-2 expression in lung, and also lowered the
incidence of alveolar dysplasia. However, aspirin failed to
decrease the proliferation of the alveolar epithelium. This
suggests that increased levels of COX-2 do not directly
lead to proliferation in the early stage of NNK-induced
tumorigenesis. Duan [44] declared that aspirin was not
able to inhibit A549 cell proliferation directly without
cytokine stimulation. In 2004, Keith et al. [45] found that
increased pulmonary production of prostaglandin I2
(prostacyclin) by lung-specific overexpression of prostacy-
clin synthase decreases lung tumor incidence and multi-
plicity in chemically-induced murine lung cancer models.
Hence, the modulation of pathways downstream of COX-
2 may be well worth exploring in lung cancer.
PEITC, a naturally occurring constituent of cruciferous
vegetables, has been reported to inhibit the development
of tobacco-specific carcinogen-induced lung tumors [46-
50]. Morse et al. [46] reported that F344 rats fed diets con-
taining PEITC (3 µmol/g diet), before and during treat-
ment with the NNK, developed about 50% fewer lung
tumors than NNK-treated rats fed control diets. The lung
tumor incidences in the NNK-treated groups, fed a diet
containing 4 mmol/kg or 8 mmol/kg PEITC, were 9% and
17% respectively, compared to 67% in the control group
[49]. In this study, we observed inhibition of lung tumor-
igenesis in Wistar rats fed with PEITC after NNK instilla-
tion. PEITC significantly lowered the incidence of alveolar
dysplasia in group B, but we observed no down-regulation
of COX-2 expression or PCNA in this group. The anticar-
cinogenic action of isothiocyanates against lung cancer
has been attributed to the inhibition of phase I enzymes
and/or to the induction of activity of phase II conjugation
enzymes for carcinogen metabolism [51-54]. In most
reported studies, PEITC must be present at the time of car-
cinogen exposure in order to inhibit tumorigenesis detect-
ably [48,55,56]. The results indicate that PEITC inhibits
the progression to alveolar dysplasia in early stages of
tumorigenesis, and the inhibitory effect may be COX-2
independent. However, a previous study concluded that
PEITC decreased COX-2 protein expression levels, leading
to reduced secretion of both pro-inflammatory mediators
in Raw 264.7 macrophages [57]. The environment is very
complex in vitro; many factors participate in tumorigene-
sis. In cell culture, COX-2 expression has proved to be
highly responsive, changing rapidly in the presence of
many growth factors, cytokines and other inflammatory
mediators. It is therefore not surprising that COX-2
expression becomes up-regulated in some circumstances.
Despite strong evidence that PEITC inhibits cancer devel-
opment, there are also reports that it induces or promotes
carcinogenesis. The molecular basis of the latter may be
PEITC-increased transactivation of activator protein 1
(AP-1) and AP-1 DNA binding [58]. In contrast, some
studies have reported that aspirin exerts antitumor effects
partly through blocking the induction of activator pro-
tein-1 (AP-1) activation by tumor promoters [59]. Our
results showed that a combination of aspirin and PEITC
reduced proliferation significantly. This could partly
explain why there was significant reduction of PCNA
expression in group C.
Lung tumorigenesis is a complex process in which many
factors participate. These finding are important for future
research into lung cancer chemoprevention and therapy
in smokers and ex-smokers with early lesions.
Conclusion
A single-dose of NNK at 25 mg/kg body weight by intrat-
racheal instillation is sufficient to induce preneoplastic
lesions in Wistar rats. COX-2 takes part in NNK-induced
tumorigenesis, but a decrease in this enzyme fails to
inhibit proliferation of the alveolar epithelium. Aspirin
and PEITC inhibit the progression of NNK-induced prene-
oplastic lesions by reducing cellular proliferation.
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